Tscan Therapeutics Stock Today
| TCRX Stock | USD 1.58 0.12 7.06% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Tscan Therapeutics is trading at 1.58 as of the 20th of March 2025; that is 7.06 percent decrease since the beginning of the trading day. The stock's open price was 1.7. Tscan Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of July 2021 | Category Healthcare | Classification Health Care |
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. The company has 52.31 M outstanding shares of which 2 M shares are at this time shorted by private and institutional investors with about 5.8 trading days to cover. More on Tscan Therapeutics
Moving together with Tscan Stock
Moving against Tscan Stock
Tscan Stock Highlights
| Thematic Ideas | (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Management, Management, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsTscan Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tscan Therapeutics' financial leverage. It provides some insight into what part of Tscan Therapeutics' total assets is financed by creditors.
| |||||
Tscan Therapeutics (TCRX) is traded on NASDAQ Exchange in USA. It is located in 830 Winter Street, Waltham, MA, United States, 02451 and employs 194 people. Tscan Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 96.2 M. Tscan Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 52.31 M outstanding shares of which 2 M shares are at this time shorted by private and institutional investors with about 5.8 trading days to cover.
Tscan Therapeutics currently holds about 125.6 M in cash with (110.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Tscan Therapeutics Probability Of Bankruptcy
Ownership AllocationTscan Therapeutics shows a total of 52.31 Million outstanding shares. The majority of Tscan Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tscan Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tscan Therapeutics. Please pay attention to any change in the institutional holdings of Tscan Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Tscan Ownership Details
Tscan Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Aberdeen Group Plc | 2024-12-31 | 883.7 K | |
| State Street Corp | 2024-12-31 | 800.9 K | |
| Dc Funds, Lp | 2024-12-31 | 630 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 412.9 K | |
| Northern Trust Corp | 2024-12-31 | 322.1 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 280 K | |
| Tocqueville Asset Management L.p. | 2024-12-31 | 260.9 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 160.7 K | |
| Bank Of America Corp | 2024-12-31 | 150.1 K | |
| Ecor1 Capital, Llc | 2024-12-31 | 5 M | |
| Blackrock Inc | 2024-12-31 | 5 M |
Tscan Therapeutics Historical Income Statement
Tscan Stock Against Markets
Tscan Therapeutics Corporate Management
| Justin McCue | Chief Officer | Profile | |
| Leiden MBA | Principal Treasurer | Profile | |
| Ray Lockard | VP Quality | Profile | |
| Ray MBA | Senior Quality | Profile | |
| Jim Murray | Senior Operations | Profile |
Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.